As biotechnology shares cratered on continued criticism from presidential candidates about rising drug prices, one hedge fund has managed to find eye-popping returns in the space.
While the iShares Nasdaq Biotechnology ETF saw an 11 percent gain in 2015, the Perceptive Life Sciences Fund posted a 51.8 percent return and was the No. 1 performing hedge fund of last year, according to a Bloomberg News ranking.
"Well, she's wrong. I understand the idea that [with] high drug prices in general, you'd rather have them low if you could, but there's a balance," Edelman said Wednesday.
He discussed his current favorite stocks on the show and, in a CNBC Pro exclusive video with Meg Tirrell, he handicapped the prospects for one particular hot biotech looking to score a big FDA win next month.